Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trialRichard Dodel, Frank Jessen, Axel Rominger et al.|The Lancet Neurology|2013Cited by 185
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkersIris E. Jansen, Pablo García‐González, Anna Zettergren et al.|Acta Neuropathologica|2022Cited by 138
<scp>EFNS</scp>‐<scp>ENS</scp>/<scp>EAN</scp> Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's diseaseR. Schmidt, Sandro Sorbi, Edith Hofer et al.|European Journal of Neurology|2015Cited by 135